PALO ALTO PRIZE
The Palo Alto Longevity Prize is a $1 million life science competition dedicated to ending aging. Ours is one of a growing number of initiatives around the world pursuing this goal—the more shots on goal the better. Through an incentive prize, our specific aim is to nurture innovations that end aging by restoring the body’s homeostatic capacity and promoting the extension of a sustained and healthy lifespan.
There are two prizes available and teams may compete for one or both prizes:
- A $500,000 Homeostatic Capacity Prize will be awarded to the first team to demonstrate that it can restore homeostatic capacity (using heart rate variability as the surrogate measure) of an aging reference mammal to that of a young adult.
- A $500,000 Longevity Demonstration Prize will be awarded to the first Team that meets all of the Prize Requirements as determined by the Judging Panel in its sole discretion, including extending the mean lifespan of a wild-type mammalian intervention cohort by 50% relative to acceptable published natural history of untreated norms in a statistically significant (p<.05) manner, using a Statistical Model (as defined and approved in the official “Competition Agreement”). The intervention and control cohorts should be age and gender matched and should include an equal number of males and females. If you would like more details on the Prize Requirements please use the contact form at the bottom of this page.
Just six decades after Orville and Wilbur Wright launched the aviation age, President Kennedy pronounced a moonshot: fly people to the moon and back. Eight years later, the mission was accomplished. Now, six decades after James Watson and Francis Crick discovered the code of life, it is time to embark on another historic mission: hack the code of life and cure aging.
See all Advisors of the Palo Alto Prize here.
The Hero Science Foundation is grateful to the support of Dr. Joon Yun, who is the benefactor of the Palo Alto Longevity Prize and the founding benefactor Hero Science Foundation. Dr. Yun is the President of Palo Alto Investors, LLC, an investment management firm founded in 1989, currently with over $2 billion in assets. He joined the firm in 1998 as a healthcare analyst. Concurrently, Joon served on the clinical faculty at Stanford from 2000-2006 as a board certified radiologist. Joon graduated from Harvard College, received his M.D. from Duke, and completed his residency and fellowship at Stanford. He has served on corporate and nonprofit boards and is a founder of the Palo Alto Institute, a private foundation and think tank. Dr. Yun has published numerous patents, peer-reviewed scientific articles, books, and is a contributor to Forbes. His writing covers several topics, including evolution, investing, and the future of healthcare. He is a contributor to Forbes. Follow him at his website at www.drjoonyun.com and at Twitter at @DrJoonYun.